STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better

At the BIO 2026 conference, biotech leaders shared worries about the competitive edge of Chinese biotech firms, the profitability challenges of integrating AI, and the sustainability of Trump-era drug pricing reforms. The discussions highlighted the industry's dual focus on technological advancement and navigating complex regulatory landscapes, underscoring the need for innovation while addressing political and economic pressures. This gathering reflects the broader biotech sector's efforts to balance growth with ethical and policy considerations.